Abstract

Solute carrier family 25 member 20 (SLC25A20) is a mitochondrial-membrane–carrier protein involved in the transport of acylcarnitines into mitochondrial matrix for oxidation. A previous-integrated-proteogenomic study had identified SLC25A20 as one of the top-three prognostic biomarkers in HCC. However, the expression and the biological function of SLC25A20 have not yet been investigated in HCC. In the present study, we found that SLC25A20 expression is frequently down-regulated in HCC cells mainly due to the up-regulation of miR-132-3p. Down-regulation of SLC25A20 is associated with a poor prognosis in patients with HCC. SLC25A20 suppressed HCC growth and metastasis, both in vitro and in vivo, by suppression of G1–S cell transition, epithelial-to-mesenchymal transition (EMT), and induction of cell apoptosis. Mechanistically, SLC25A20 down-regulation promoted HCC growth and metastasis through suppression of fatty-acid oxidation. Altogether, SLC25A20 plays a critical tumor-suppressive role in carcinogenesis of HCC; SLC25A20 may serve as a novel prognostic factor and therapeutic target for patients with HCC.

Details

Title
Down-regulation of SLC25A20 promotes hepatocellular carcinoma growth and metastasis through suppression of fatty-acid oxidation
Author
Yuan, Peng 1 ; Jiao, Mu 2 ; Wang, Zijun 3 ; Ma Shuaijun 4 ; Xiuwei, Da 5 ; Song, Jian 6 ; Zhang, Hongxin 5 ; Yang, Le 7 ; Li, Jibin 8 ; Yang, Jingyue 9 

 Air Force Military Medical University, Department of Pain Treatment, Tangdu Hospital, 710038, Xi’an, China (GRID:grid.460007.5) (ISNI:0000 0004 1791 6584); Air Force Military Medical University, State Key Laboratory of Cancer Biology and Department of Physiology and Pathophysiology, 710032, Xi’an, China (GRID:grid.233520.5) (ISNI:0000 0004 1761 4404) 
 The First Affiliated Hospital of Chongqing Medical University, Department of Hematology, 400016, Chongqing, China (GRID:grid.452206.7); Department of Hematology, Xi’an Central Hospital, 710003, Xi’an, China (GRID:grid.478124.c) 
 Air Force Military Medical University, Department of Pain Treatment, Tangdu Hospital, 710038, Xi’an, China (GRID:grid.460007.5) (ISNI:0000 0004 1791 6584); Battalion of the first Regiment of cadets of Basic Medicine, Air Force Military Medical University, 710032, Xi’an, China (GRID:grid.460007.5) 
 Air Force Military Medical University, Department of Urology, Xijing Hospital, 710032, Xi’an, China (GRID:grid.417295.c) (ISNI:0000 0004 1799 374X) 
 Air Force Military Medical University, Department of Pain Treatment, Tangdu Hospital, 710038, Xi’an, China (GRID:grid.460007.5) (ISNI:0000 0004 1791 6584) 
 Air Force Military Medical University, Department of Hepatobiliary Surgery, Xijing Hospital, 710032, Xi’an, China (GRID:grid.417295.c) (ISNI:0000 0004 1799 374X) 
 Air Force Military Medical University, Precision Pharmacy and Drug Development Center, Department of Pharmacy, Tangdu Hospital, 710038, Xi’an, China (GRID:grid.460007.5) (ISNI:0000 0004 1791 6584) 
 Air Force Military Medical University, State Key Laboratory of Cancer Biology and Department of Physiology and Pathophysiology, 710032, Xi’an, China (GRID:grid.233520.5) (ISNI:0000 0004 1761 4404) 
 Xijing Hospital, Air Force Military Medical University, Department of Oncology, 710032, Xi’an, China (GRID:grid.417295.c) (ISNI:0000 0004 1799 374X) 
Publication year
2021
Publication date
Apr 2021
Publisher
Springer Nature B.V.
e-ISSN
20414889
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2509109180
Copyright
© The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.